ClinicalTrials.gov
public full text
Public Domain
Rosuvastatin (Crestor) in Friedreich Ataxia
This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting#849785
- Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI#848066
- Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects#1102780
- Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia#1112976
- Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin#891789
Record · ID 1009637
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive